A MULTICENTER RETROSPECTIVE STUDY TO UNDERSTAND THE CLINICAL CHARACTERISTICS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: INTERIM RESULTS FROM THE CREEK STUDY

Introduction: The rapidly expanding treatment landscape for Chronic Lymphocytic Leukemia (CLL) calls appropriate patient and selection sequencing with existing agents. Data describing CLL management are fragmented across different regions, marked cross-country differences in practices outcomes. Therefore, we have established the observational study CREEK, retrospective real-world evidence key data from Middle East North Africa, Asia, Latin America. This interim analysis aimed to describe disease characteristics of CLL-treated (CLL-Tx) patients international countries treatment-naïve (CLL-N) Gulf Cooperation Council (GCC) states. Methods: 976 were collected, including 845 CLL-Tx who started between 01 June 2016 12 months before collection a pilot cohort 131 CLL-N patients. Patients’ demographics, characteristics, laboratory assessments, comorbidities recorded. Results: average age was 63.5 63.4 years, respectively. Most males, 66.7% 71.0% CLL-N. Around 11% 12% current smokers. (62%) had an Eastern Cooperative Oncology Group (ECOG) score 0 or 1, same (56.4%). As per Cumulative Illness Rating Scale (CIRS), moderate severe musculoskeletal (p < 0.0025), endocrine-metabolic 0.0001) more frequent CLL-Tx. All parameters, except neutrophils eGFR categories, showed significant difference 0.05) days diagnosis enrollment 475 59 0.0001), Patients worse prognosis compared based on Rai Binet Staging Scores 0.0001). testing rate IGHV mutation status low, 23.5% 38.9% CLL-N, percentage mutated significantly lower = 0.0006) (9.8%) (26.7%). Whereas cytogenetic abnormalities (del “17p”—del “11q”—Complex karyotype), TP53 Aberrations, aberrations “17p” aberrations—TP53 without del “17p”) didn’t show > Conclusions: demonstrated preliminary understanding that comparable demographic characteristics; however, higher prevalence comorbidities, ECOG scores, staging IGHV. Keywords: chronic lymphocytic leukemia (CLL), naïve, research funded by AstraZeneca UK Limited Conflict interest P. Kantharaju Employment leadership position: Pushpalata is employee F. J Gonzalez Francisco A. Ishikawa Akemi